Short vs long treatment for stage II-III rectal cancer with dMMR
Part of Cancer, Digestive system clinical trials.
This trial tests how long you need a PD-1 immunotherapy before surgery for a specific type of rectal cancer (dMMR/MSI-H). It looks at whether a shorter or longer course works best. This could mean fewer side effects and a quicker path to surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You must have stage II or III rectal cancer that is dMMR or MSI-H (a certain gene pattern).
- You cannot have had any cancer treatment before, like chemo, radiation, or immunotherapy.
- You must be in good general health (able to do daily activities, with a score of 0 or 1 on a standard health scale).
- Your main organs (heart, lungs, liver, kidneys, bone marrow) must work well, shown by specific blood test results.
- You cannot have active autoimmune disease, Lynch syndrome, serious heart problems, or certain infections (like hepatitis or HIV).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving immunotherapy (pembrolizumab) before surgery can help treat stage I-III colon cancer that has a specific genetic feature (dMMR). The goal is to see if this approach can reduce the amount of surgery needed or improve outcomes.
This trial tests a shorter course of radiation that avoids draining lymph nodes, followed by an immunotherapy drug (PD-1 inhibitor), for people with stage II or III rectal cancer that is mismatch repair proficient (pMMR) or microsatellite stable (MSS). The goal is to see if this approach can shrink tumors while keeping lymph nodes intact.
This trial studies whether immunotherapy (nivolumab plus ipilimumab) can help people with early-stage rectal cancer that has dMMR or MSI changes. It’s meant for patients who have not yet had chemotherapy, radiation, or immunotherapy for colorectal cancer.
This trial compares a new treatment approach—short-course radiation followed by an immunotherapy drug (PD-1 inhibitor) and chemotherapy (FOLFOX)—to the standard long-course chemoradiation for people with a specific type of advanced rectal cancer that is pMMR/MSS. The goal is to see if the shorter treatment works as well or better.
This trial tests if adding an immunotherapy drug (PD-1 inhibitor) and a targeted therapy (bevacizumab) to short-course radiation followed by chemo can improve outcomes for patients with locally advanced rectal cancer that is pMMR/MSS. The goal is to shrink the tumor before surgery and possibly avoid the need for more extensive treatment.
This phase 3 trial studies a PD-1 antibody medicine given after surgery to help prevent stage III colon cancer from coming back. It is specifically for people whose tumor is mismatch repair–defective (dMMR) or MSI-H, which may make the cancer more responsive to immune-based treatment.
Hear when a new Immune-related Adverse Event trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.